Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

(2014) Hee Jin Lee et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

(2013) Lise Roca et al.   BREAST CANCER RESEARCH AND TREATMENT

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

(2013) Branka Petricevic et al.   Journal of Translational Medicine

Analysis of Fc  Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

(2012) S. A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

(2011) D. M. Collins et al.   ANNALS OF ONCOLOGY

High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas

(2011) M. R. Zocchi et al.   BLOOD

Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

(2010) K. Tamura et al.   ANNALS OF ONCOLOGY

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

(2010) Toru Mukohara   CANCER SCIENCE

Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR)

(2010) B. Z. ALIZADEH et al.   JOURNAL OF RHEUMATOLOGY

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine